Professor Neville Sanjana
Professor Neville Sanjana is a core faculty member at the New York Genome Center and Professor in the Departments of Biology and of Neuroscience and Physiology at New York University. As a bioengineer, Professor Sanjana has developed high-throughput genome engineering tools to understand the impact of genetic changes on cancer evolution, viral pathogenesis, drug resistance and the nervous system. Recent work from his laboratory has identified synthetic cell programmes to enhance cell therapies for blood cancers and solid tumours and developed new methods to identify causal noncoding variants and their target genes at scale.
A proud recipient of numerous prestigious industry awards and the Leichtung Family Investigator of the Brain and Behavior Foundation, Professor Sanjana is also a co-founder and advisor to OverT Bio and a member of the Scientific Advisory Board of QIAGEN. He holds a PhD in brain and cognitive sciences from MIT, a BS in symbolic systems and a BA in English from Stanford University.
ArticleTurning GWAS signals into drug targets with scalable CRISPR
Genome-wide association studies have linked thousands of genetic variants to disease, yet most remain disconnected from drug-relevant biology. Neville Sanjana, Professor at New York University and Core Faculty Member at the New York Genome Center, explains how scalable CRISPR screens systematically link noncoding variants to causal genes and therapeutic targets.